We previously developed bioluminescence resonance energy transfer (BRET) biosensors to detect interaction between RAF family kinase domains 6
. In a screen interrogating a human kinome library, we identified MEK1 and MEK2 as specific inducers of BRAF-KSR1 kinase domain dimeri zation (Fig. 1a , Extended Data Fig. 1a and Supplementary Table 1 ). We confirmed these findings by BRET and co-immunoprecipitation (co-IP) (Extended Data Fig. 1b-d) . Conversely, depletion of endo genous MEK1 and MEK2 reduced the BRAF-KSR1 interaction (Extended Data Fig. 1e, f) . Intriguingly, MEK promoted BRAF-KSR1 dimerization independent of its catalytic function ( Fig. 1b and Extended Data Fig. 1g, h ). These findings led us to assess the impact of MEK on other RAF biosensor pairs. Notably, heterodimers of BRAF-KSR1 and BRAF-KSR2 were by far the most responsive, which cannot be explained by the strict conservation of the dimer interface across RAF family members (Extended Data Fig. 1i -k) 5 . We hypothesized that MEK modulates dimer formation by interacting directly with KSR1 and/or BRAF kinase domains. Previous work showed that MEK1 binds KSR2 and BRAF in a similar 'face-to-face' manner involving their αG helices and activation segments (Extended Data Fig. 2a ) 7, 8 . Using yeast two-hybrid (Y2H) screening, we identified the F311S mutation in MEK1 that abrogated KSR1, BRAF, and CRAF binding (Extended Data Fig. 2b, c) . In KSR1, we isolated the W831R mutation that impeded MEK1 binding (Extended Data Fig. 2d ). Both mutations mapped to the contacting αG helices 7 and neither adversely affected protein fold (Extended Data Figs 2a and 3a-f). Consistent with available structures 7, 8 , the I666R mutation in BRAF (analogous to KSR1 W831R ) also abolished binding to MEK1 (Extended Data Fig. 2d ). We next tested the mutations for effects on BRAF-KSR1 heterodimerization. MEK1
F311S did not induce BRAF-KSR dimerization ( Fig. 1c and Extended Data Fig. 1l ), and KSR1 W831R could not be induced to dimerize with BRAF by MEK1 (Fig. 1d) . In contrast, BRAF I666R could be induced to dimerize with KSR1 by MEK1 (Fig. 1d ). Similar results were obtained by co-IP using full-length proteins (Fig. 1e , compare lanes 3, 9, 11, and 13). The near-stoichiometric interaction between BRAF, KSR1, and MEK1 supported the notion that the examined interactions were strong and direct (Extended Data Fig. 3g, h) . Perturbation of the side-to-side dimerization surface on KSR and BRAF kinase domains (BRAF_R509H or KSR1_R665H mutations) also abolished MEK-induced KSR1-BRAF dimerization (Fig. 1e , compare lanes 3, 5, and 7). Thus, the ability of MEK1 to promote BRAF-KSR1 association was dependent on KSR-MEK interaction and on the side-to-side dimerization surface of BRAF and KSR kinase domains 5 . We next investigated the effect of MEK1 on the catalytic output of BRAF-KSR1 dimers. MEK1 promoted the ability of KSR1 to transactivate BRAF in a kinase domain dimerization-dependent manner (Fig. 1e , phosphorylated MEK (pMEK) panel, compare lanes 3, 5 and 7, and Extended Data Fig. 4a ). This held true also for KSR2 (Extended Data Fig. 4b ). In contrast, when binding of MEK1 to KSR was disabled as in KSR1 W831R , MEK1 no longer promoted KSR1-mediated BRAF transactivation (Fig. 1e , compare lanes 3 and 9, and Extended Data Fig. 4c ). Analogous findings were obtained with Drosophila RAF and KSR (Extended Data Fig. 4d, e) . Likewise, the BRAF I666R mutation that disabled MEK1 binding also prevented MEK phosphorylation (Fig. 1e , compare lanes 3 and 11, and Extended Data Fig. 4c ). Notably, MEK phosphorylation required a catalytically competent BRAF, while mutations to the active site region of KSR1 had no effect (Extended Data Fig. 4f ). Finally, two KSR1 gain-of-function mutations (KSR1 AF and KSR1 AFDDEE ) 9 also required MEK binding for endogenous BRAF transactivation (Extended Data Fig. 4g ). Thus, BRAF transactivation by KSR1 also depended on KSR-MEK interaction and on the ability of BRAF and KSR kinase domains to engage in side-to-side dimers.
We envisioned two models for how MEK1 binding to KSR1 potentiates the ability of KSR1 to promote BRAF phosphorylation of MEK1. In the first model, KSR1 functions as a scaffold to present an αG-bound MEK1 to the active site of BRAF while the kinase domains of KSR1 and BRAF engage each other as a side-to-side dimer. This would require considerable structural rearrangement because the configuration of a BRAF-KSR dimer would orient the KSR-bound MEK away from the BRAF catalytic site. A solution to this conundrum would be the involvement in trans of an active BRAF dimer as previously suggested 7 and exemplified in Fig. 2a (model 1) . However, as the KSR-MEK binding mode secludes the activation segment of MEK in an anti-parallel β-sheet, this too would require substantial conformational change to free the MEK phospho-acceptor sites. In a second more likely model, MEK1 binding to the KSR1 kinase domain through helix αG would support the ability of KSR1 to allosterically transactivate BRAF by side-to-side dimerization, allowing BRAF to phosphorylate a second MEK1 molecule engaged by helix αG of BRAF. This model presupposes the existence of two functionally distinct MEK molecules, namely, an 'activator' MEK that binds to KSR1 and stimulates dimerization with BRAF, and a 'substrate' MEK that is engaged and phosphorylated by activated BRAF (Fig. 2a, model 2) .
To test the second model, we identified MEK1 mutants that bind KSR1 W831R , and thus would be functionally distinguishable from wild-type (WT) MEK1, which binds only WT KSR1 and BRAF. We reasoned that if we restored binding of MEK1 to KSR1 W831R , such MEK1 mutants might regain the ability to induce KSR1 W831R dimerization with BRAF and thus promote BRAF catalytic function. Using Y2H screening, we retrieved MEK1 variants harbouring M219V, N221Y, or M219W-A220L substitutions that restored interaction with KSR1 W831R , with the M219W-A220L variant to nearly WT levels (Fig. 2b, Extended Data Fig. 5a , b and Supplementary Table 2 ). These mutations also increased binding to endogenous KSR1, BRAF, and CRAF (Extended Data Fig. 5c ). As expected, and in contrast to WT MEK1, MEK1
M219W-A220L promoted BRAF-KSR1 W831R dimerization ( Fig. 2c and Extended Data Fig. 5d ) and induced BRAF activation (Fig. 2c) . Thus, restoration of binding of MEK1 to an αG-defective KSR1 mutant was sufficient to rescue its ability to transactivate BRAF.
We took advantage of the MEK1 M219W-A220L mutant to determine whether BRAF can phosphorylate WT MEK1 molecules not engaged directly by KSR1. We introduced a longer Myc epitope (called 8GS) at the N terminus of WT MEK1 to distinguish it by size from MEK1 M219W-A220L (Extended Data Fig. 5e ). Since WT MEK1 cannot associate with KSR1 W831R , it did not promote BRAF transactivation (Fig. 1e) . We next co-expressed 8GS-MEK1
WT and MEK1 M219W-A220L in the presence of BRAF and KSR1 W831R . Notably, in contrast to WT MEK1 alone, the presence of MEK1 M219W-A220L led to the phosphorylation of 8GS-MEK1 WT (Fig. 2d , compare lanes 7 and 8). This required both BRAF and KSR1 W831R because no phosphorylation was detected in the absence of each (Fig. 2d , compare lane 8 with lanes 2, 4, and 6). Moreover, the effect was abrogated when the R665H mutation was introduced in KSR1 W831R (Fig. 2d , compare lanes 8 and 9). Given that 8GS-MEK1
WT cannot associate with KSR1 W831R , this result provided compelling evidence for two functional forms of MEK1: namely one molecule of MEK1 (exemplified by MEK1 M219W-A220L ) that bound to KSR to enable transactivation of BRAF and a second molecule of MEK1 that functioned as a substrate of BRAF. These results supported model 2 (Fig. 2a) .
We next investigated whether the ability of MEK1 to selectively induce BRAF transactivation by KSR held true for the full-length proteins. We conducted bi-directional titration experiments in the presence of MEK1 using full-length BRAF, CRAF, and KSR1. Markedly, BRAF and KSR1 co-expression led to robust pMEK levels, whereas BRAF-CRAF or CRAF-KSR1 co-expression had a marginal effect (Fig. 3a) . Furthermore, MEK1 only weakly promoted full-length CRAF-KSR1 dimerization (Extended Data Fig. 6a ). Despite the fact that the effect of MEK1 on dimerization was readily selective for BRAF-KSR kinase domain pairs (Extended Data Fig. 1i-k) , we nonetheless questioned whether other domains participated in the context 
Anti-pMEK of full-length proteins as suggested previously 10 . Using co-IP, we tested the interactions between the N-terminal regulatory regions (NTRs) of BRAF, CRAF, and KSR1. Interestingly, KSR1
NTR interacted with BRAF NTR as well as with itself, but barely with CRAF NTR (Fig. 3b ). The same trend was observed in BRET and Y2H analyses (Extended Data Fig. 6b, c) . Thus, we concluded that the NTRs of BRAF and KSR1 also have the potential to support selective heterodimer formation. Incidentally, the NTR of KSR1 also appeared to enable KSR1 homodimerization.
We next tested NTR truncation mutants by co-IP to narrow down the domains/motifs involved. In BRAF, sequences encompassing a conserved region called the BRAF-specific (BRS) domain 3 and the cysteine-rich domain (CRD) were both required (Extended Data Figs 6d, e and 7a, b). Likewise, two areas within the KSR1 NTR encompassing the conserved CC-SAM and CRD domains were required for optimal binding (Extended Data Figs 6d, f and 7a, c). Using Y2H and BRET, we detected a specific interaction between the BRS and CC-SAM domains (Extended Data Fig. 7d , e) while the BRS did not self-associate (Extended Data Fig. 7e ). Moreover, fusion of the cognate CRDs to the BRS and CC-SAM domains enhanced this interaction, whereas the isolated CRDs did not associate (Extended Data Fig. 7d ). Interestingly, swapping the BRS and the CC-SAM domains between BRAF and KSR1 led to productive BRAF-KSR1 interaction and transactivation (Extended Data Fig. 7f ). Conspicuously, the BRS is absent from the NTRs of ARAF and CRAF and its insertion into CRAF considerably augmented CRAF-KSR1 dimerization and CRAF transactivation ( ) between the coiled-coil regions in the form of a four-helix bundle ( Fig. 3d and Extended Data Fig. 9c ). Satisfyingly, the contact surface used by the CC-SAM domain in the crystal structure was identical to that mapped by NMR ( Fig. 3d and Extended Data Fig. 8g ).
The binding between the BRS and CC-SAM domains was mediated by a mixture of hydrogen bonds and salt interactions (Fig. 3d ). In addition, each end of the elongated contact surface was anchored by a cluster of hydrophobic interactions (Fig. 3d) . We note that binding of the BRS and CC-SAM domains correlated with major changes to the CC-SAM domain (root-mean-square deviation = 2.59 Å) and minor changes to the BRS domain (root-mean-square deviation = 0.79 Å) (Supplementary Video 1). Next, we validated the BRS:CC-SAM binding mode by mutagenesis. Point mutations targeting hydrophobic interactions in the mCC-SAM domain (L45D and C60D, corresponding to L47D and C62D in hKSR1) or in the BRS domain (M53D) impaired BRS:CC-SAM domain interaction as assessed by HSQC and by BRET (Extended Data Fig. 10a, b) . The mutations also reduced the ability of full-length BRAF to associate with KSR1 and compromised MEK phosphorylation (Fig. 3e) . Furthermore, singlesite charge reversal mutations disrupting the E72
BRS ionic pair also abrogated interaction and activity ( We were intrigued that full-length BRAF and KSR1 and KSR2 required MEK for heterodimerization (Fig. 1) , whereas the isolated NTRs interacted independent of MEK (Extended Data Fig. 10d ). Previous work showed that, in quiescent cells, the NTRs of BRAF and CRAF associate with their kinase domains to enforce a repressed state, and this was released upon RAS-GTP binding to their RASbinding domains (RBDs) [11] [12] [13] . This self-interaction might restrain the NTRs from interacting in trans with other NTRs. We recently found that the NTRs and kinase domains of KSR proteins also interact 14 but the absence of an RBD would preclude a direct response of this interaction to RAS-GTP. We reasoned that the ability of KSR1 and KSR2 kinase domains to stably associate with MEK might serve as a release mechanism. Consistent with this hypothesis, we observed by co-IP that the KSR1 NTR-kinase domain interaction was progressively disrupted by MEK1 dosage (Fig. 4a) . This effect was not observed with the MEK1 F311S mutant disabled for KSR1 binding and was also independent of ERK-dependent feedback 15 as ERK inhibition had no effect (Fig. 4a) . Consistent with the absence of an RBD in KSR proteins, KRAS G12V expression had no effect (Fig. 4a) . In sharp contrast, for BRAF the NTR-kinase domain interaction was only marginally perturbed by MEK1 expression, but potently disrupted by KRAS G12V (Fig. 4b) . These results supported the notion that, unlike BRAF, the NTR-kinase domain interaction in KSR1 was not directly responsive to RAS-GTP, but was responsive to the binding of MEK1 (Fig. 4a) . Thus, binding of MEK1 to KSR1 may free its NTR for subsequent interaction with BRAF or with a second KSR1 molecule (Extended Data Fig. 10e, f) .
Collectively, these findings challenge the common view that KSR proteins are scaffolds that enable MEK phosphorylation by bridging MEK and RAF and instead support a model whereby KSRs function as MEK-dependent allosteric activators of BRAF (Fig. 4c) . These findings also identify the RAF family NTRs as potential targets for therapeutic intervention that may afford a more favourable route than the kinase domains to selectively modulate RAS-ERK signalling in cancers.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment Plasmids and RNA interference reagents. Mammalian expression plasmids were all made in the pCDNA3.1-Hygro backbone (Invitrogen). Pyo-and Myc-encoding sequences were added by PCR and the corresponding fusions were cloned between KpnI and XbaI. GFP10-, RlucII-, mCherry-, and Flag-encoding sequences were inserted at the 5′ or 3′ end of ORFs by cloning them between KpnI and XbaI sites in plasmids containing the relevant cassette. RAF family kinase domain BRET fusion constructs were generated by inserting the RlucII or GFP10 moieties at the N terminus of the kinase domain (ARAF , BRAF , CRAF , KSR1 , and KSR2 ) and followed by a C-terminal KRAS CAAX-box as previously reported 6 . NTRs (BRAF and CRAF 1-326 , KSR1 1-558 ) BRET constructs have the RlucII or GFP10 moieties fused at their C terminus. Y2H bait plasmids were based on pGBKT7 while prey plasmids were generated in pGADT7 (Clontech). Y2H constructs corresponding to KSR1 , MEK1, BRAF , and CRAF were cloned between NdeI and BamHI sites, while BRAF , CRAF , and KSR1 were cloned between NdeI and EcoRI sites. Plasmids used to express Drosophila RAF and KSR protein fusions were described previously 5 . For bacterial expression, the human BRS (BRAF ) was cloned in a pGEX-2T-based expression vector with an N-terminal TVMV (TEV) protease-cleavable glutathione S-transferase (GST) tag (pGEX-TEV-BRS). Human and mouse KSR1 CC-SAM domains were cloned in pPROEX-HTa with an N-terminal TVMV (TEV) protease-cleavable 6× His tag. All mutations were inserted using a QuickChange II Site-Directed mutagenesis kit (Agilent). All constructs were fully verified by Sanger sequencing.
The Broad Institute kinase ORF library was obtained from Addgene in pDONR-223 entry vectors (http://www.addgene.org/human_kinases) 16 . pDONR-223 plasmids were purified with a QIAprep Miniprep Kit (Qiagen). cDNAs were then transferred in the Gateway-compatible pLX301 lentiviral vector (Addgene) by using LR Clonase enzymatic recombination according to the manufacturer's protocol (Invitrogen). pLX301 allows for expression of untagged kinase ORFs from a CMV promoter. The kinase ORF library in pLX301 was then purified with QIAprep Miniprep Kit (Qiagen) and arrayed in eight 96-well plates at a concentration of 10 ng ml . Control lentiviruses (empty pLX301 and pLKO.1-CMVTurboGFP) were included in each plate.
shRNA expression constructs were in the pLKO.1-puro backbone 17 . The sequences of the shRNA reagents used in this study were as follows: shControl (SHC002; 5′-CAACAAGATGAAGAGCACCAA-3′); shMEK1 (TRCN0000002329; 5′-GCTTCTATGGTGCGTTCTACA-3′); shMEK2 (TRCN0000007006; 5′-GACTATATTGTGAACGAGCCA-3′); Cell culture, transfection, and lentiviral infections. HEK293T and HeLa cells were obtained from the Institute for Research in Immunology and Cancer high-throughput screening platform (University of Montréal, Montréal, Canada), which were originally purchased from Sigma-Aldrich (catalogue numbers 12022001-1VL and 93021013-1VL, respectively). They were routinely tested for mycoplasma contamination. Cells were maintained in DMEM supplemented with 10% FBS at 37 °C and under 5% CO 2 . For BRET experiments, 1.5 × 10 5 cells per well were plated overnight in 12-well plates and transfected the next day with the appropriate constructs using PEI (25 μg ml ). Cells were transduced at a multiplicity of infection of 5 for 24 h after which puromycin selection (2 μg ml Lentiviral production for shRNA expression was done as follows. Two million HEK293T cells were plated in T75 flasks. The next day, cells were transfected with 5 μg of pLKO.1-shRNA, 6 μg of pΔ8.9 (gag, pol) and 700 ng of pCMV-VSVG using PEI (25 μg ml ) and crystal violet staining using standard procedures.
To produce kinase ORF library lentiviral particles, HEK293T cells were seeded in 96-well plates. The next day, cells were transfected using a Biomek FX instrument with 100 ng of pLX301-KinaseX, 100 ng of psPAX2 (gag, pol), and 10 ng of pMD2G using TransIT-LT1 transfection reagent (Mirus). Viral supernatants were harvested 72 h after transfection. Lentiviral production was confirmed by robotically establishing semiquantitative titres on HeLa cells after puromycin selection (2 μg ml ) followed by crystal violet staining using standard procedures. BRET experiments. BRET titration and dose-response experiments were conducted as previously described 6 . Briefly, 48 h after transfection using appropriate BRET constructs, cells were washed once and resuspended in Hank's balanced salt solution (Wisent). Cells were next transferred to white opaque microtitre plates (Greiner). Total GFP10 levels were measured using an EnVision plate reader with a 400 nm excitation filter and a 510 nm emission filter. Total mCherry levels were detected on a FlexStation II (Molecular Devices) with excitation and emission peaks set at 580 and 635 nm, respectively. A final concentration of 2.5 μM of Coelenterazine 400a (Biotium) was then added to the plates and, following 15 min of incubation, BRET signals were acquired using a VICTOR Light plate reader (Perkin Elmer) equipped with BRET2 emission filter set (donor: 410 ± 70 nm; acceptor: 515 ± 20 nm). At least three independent biological replicates of each BRET experiment were performed. For all BRET experiments, individual technical replicates corresponding to three independent transfections (n = 3) from one representative experiment are presented. BRET lentiviral ORF kinase library screening. HEK293T cells were robotically seeded into 96-well tissue culture plates (Corning) in DMEM without phenol red (Wisent) supplemented with 10% FBS and 1% penicillin/streptomycin supplemented with polybrene (4 μg ml −1 ), followed immediately by robotically arraying individual kinase-encoding lentiviruses of the CCSB-Broad Institute kinome library (20 μl per well). After incubation for 24 h, media and virus suspension were aspirated and replaced with complete growth media containing puromycin (2 μg ml ) to select for kinase ORF-expressing cells. Forty-eight hours after puromycin selection, cells were passed 1:5 in 96-well white opaque plates (Greiner) in DMEM without phenol red (Wisent) supplemented with 10% FBS and 1% penicillin/streptomycin (Invitrogen). The next day, cells were transfected with appropriate BRET constructs using TransIT-LT1 transfection reagent (Mirus). Two days after transfection, BRET measurements were performed. Total GFP10 levels were measured using an EnVision plate reader (PerkinElmer) with a 400 nm excitation filter and a 510 nm emission filter. BRET signals and luciferase activity were acquired 15 min after addition of 2.5 μM Coelenterazine 400a (Biotium) using a Synergy NEO plate reader (BioTek) equipped with BRET2 filters. After BRET readings, cell viability was assessed by addition of WST-1 reagent (1:20 dilution) followed by 30 min incubation and subsequent quantification on an EnVision plate reader (PerkinElmer). BRET calculations. BRET signals correspond to the light emitted by the GFP10 acceptor construct (515 ± 20 nm) upon addition of Coelenterazine 400a divided by the light emitted by the RlucII donor construct (410 ± 70 nm). Signals referred to as BRET2 in the text and figures correspond to total BRET2 signals measured from donor (RlucII fusion) plus acceptor (GFP10 fusion) expressing samples minus the background BRET2 signal emitted by donor alone expressing samples. Total intrinsic GFP10 (expressed as relative fluorescence units) and RlucII (relative luminescence units) signals were used as a proxy to ensure that similar protein levels were compared between analogous probes. In titration experiments where the amount of GFP10 acceptor construct varied, BRET2 (y axis) was plotted as a function of the ratio of total GFP10 signal in relative fluorescence units (
[acceptor])/total luciferase signal in relative luminescence units ([donor]) (x axis: [acceptor]/[donor]).
BRET-based dose-response experiments were presented as BRET2 fold-change, which was calculated by dividing the BRET2 signal emitted by cells transfected with a given construct by the BRET2 signal of control cells. For mCherry fusion dose-response experiments, BRET log 2 -transformed fold-changes were reported as a function of log 10 -transformed mCherry relative fluorescence units. Co-IP and western immunoblotting. Co-IP and western immunoblotting procedures were essentially conducted as follows. To prepare cell lysates, cells were washed once in cold 1× PBS and then directly lysed on plates by adding 1 ml of Triton lysis buffer (50 mM Tris at pH 7.5, 150 mM NaC1, 10% glycerol, 0.2% Triton X-100, 1 mM EDTA, 1× phosphatase inhibitor cocktail (Sigma-Aldrich), 1 mM sodium vanadate, 20 μM leupeptin, aprotinin (0.15 U ml ), 1 mM phenylmethylsulfonyl fluoride (PMSF)). Lysing cells were incubated for 20 min at 4 °C with gentle rocking, collected and spun at 14,000g, 4 °C for 10 min. For co-IPs, 1 μl of anti-Flag M2 (Sigma-Aldrich) or 50 μl of anti-Pyo primary antibody (hybridoma supernatant) was added to fresh cell lysates along with 12.5 μl of protein A/G agarose beads (Calbiochem) and gently rocked at 4 °C for 4 h or overnight. Immunoprecipitates were washed three times with cold lysis buffer. IPs and cell lysates were then boiled in gel loading buffer for 5 min and resolved on 7%, 10%, or 12% SDS-PAGE depending on the molecular mass of the target proteins. Gels comprising immunoprecipitation samples were transferred to PVDF membranes (GE Healthcare), whereas gels comprising cell lysates were transferred to nitrocellulose membranes (Pall Corporation). Membranes were then blocked with 2% BSA (Sigma-Aldrich) diluted in Tris-buffered saline. Blocked membranes were then probed using appropriate primary antibodies. All antibodies were diluted in Tris-buffered saline supplemented with 0.2% Tween 20. Anti-phospho-MEK (Cell Signaling Technology; catalogue number 9121), anti-MEK1/2 (Cell Signaling Technology; catalogue number 9122), anti-BRAF (Santa Cruz; catalogue number Letter reSeArCH sc-9002), anti-CRAF (BD-Millipore; catalogue number 610152), anti-KSR1 (Abcam; catalogue number ab68483), anti-MEK1 (BD-Millipore; catalogue number 610121), anti-MEK2 (BD-Millipore; catalogue number 610235), anti-GFP (Santa Cruz; catalogue number sc-8334), anti-Ras (Abcam; catalogue number ab108602), anti-HSP90 (New England Biolabs; catalogue number 4877), anti-CDC37 (Santa Cruz; catalogue number sc-13129) and anti-pan-14-3-3 (Cell Signaling Technology; catalogue number 8312) were used at a 1:2,000 dilution. Anti-V5 (Invitrogen; catalogue number 46-0705) was used at a 1:5,000 dilution. Anti-Flag M2 (Sigma-Aldrich; catalogue number F1804) was used at a 1:20,000 dilution. Anti-Myc (9G10) and anti-Pyo 19 supernatants from hybridomas were used at a 1:10 dilution. Anti-haemagglutinin (12CA5) supernatant from hybridoma was used at a 1:5,000 dilution. Secondary anti-mouse and anti-rabbit-HRP (Jackson Immunoresearch Laboratories; catalogue numbers 115-035-146 and 111-035-144, respectively) were respectively used at 1:10,000 and 1:20,000 dilutions in Tris-buffered saline supplemented with 0.2% Tween 20. At least three independent biological replicates of each co-IP experiment were performed. One representative example is presented in the figures and gel source data are available in Supplementary Fig. 1 .
Proteins loaded on SDS-PAGE for silver staining were immunoprecipitated using anti-Flag M2 affinity gel (Sigma). Proteins of interest were isolated from the gels and identified by mass spectrometry. Desthiobiotin-ATP binding experiments. ATP-binding protein enrichment was performed using an ActivX ATP probe (desthiobiotin-ATP) following Pierce's Kinase Enrichment Kit (Thermo-Fisher Scientific) instructions with the exception that cell lysis was conducted using Triton lysis buffer (50 mM Tris at pH 7.5, 150 mM NaC1, 10% glycerol, 0.2% Triton X-100, 1 mM EDTA, 1× phosphatase inhibitor cocktail (Sigma-Aldrich), 1 mM sodium vanadate, 20 μM leupeptin, aprotinin (0.15 U ml
), 1 mM PMSF) and biotinylated proteins were captured on Streptavidin Sepharose High Performance Resin (GE Healthcare). Y2H methods. Yeast cell growth, transformation, and DNA extraction were performed using standard procedures. Strains used for Y2H experiments were systematically PJ69-4a or PJ69-4α 20 . Yeast cells were grown at 30 °C. Synthetic dextrose (SD) medium was SD-Trp, SD-Leu, SD-Trp-Leu (SD-TL), SD-TrpLeu-Ade (-TLA), or SD-Trp-Leu-His (SD-TLH) (0.67% Yeast Nitrogen Base, 2% glucose, indicated amino acids drop-out). Rich medium was YPD (1% yeast extract, 2% peptone, 2% dextrose). For Y2H interaction screening, bait (pGBKT7) and prey (pGADT7) plasmids were transformed in the haploid PJ69-4a and PJ69-4α, respectively (transformants were selected on SD-Trp for pGBKT7 and SD-Leu for pGADT7) 21 . Diploids carrying both plasmids were created by mating on YPD followed by replica plating on SD-TL, SD-TLH, or SD-TLA.
Identification of KSR1 and MEK1 binding-defective mutants was performed by reverse two-hybrid screening in haploid PJ69-4a cells containing either pGADT7-KSR1 or pGBKT7-MEK1 plasmids. By mapping individual mutations to previously solved crystal structures, we identified one substitution in each kinase domain that targeted surface-exposed residues on the αG helix (Extended Data Fig. 2b) . Briefly, random mutations were initially introduced in KSR1 602-921 or in MEK1 cDNAs using error-prone PCR with Taq DNA polymerase in the presence of dITP 22 . Linearized pGBKT7 or pGADT7 empty plasmids were digested with NdeI and BamHI before in vivo homologous recombination with mutagenized PCR products in PJ69-4a containing the bait plasmid of interest (either pGADT7-KSR1 602-921 or pGBKT7-MEK1). For library generation, the PCR:plasmid molar ratio was set at 3:1. Yeast transformants were plated on SD-TL media at approximately 1,000 colony forming units per plate. Plates were incubated for 3 days at 30 °C and then replicaplated onto SD-TLH and SD-TLA media to screen for desired mutants. Mutant colonies were selected for auxotrophy on SD-TLH and/or SD-TLA media picked and streaked for single colonies on SD-TL. Confirmation of the mutant phenotype was performed by spotting assay on SD-TL, SD-TLH, and SD-TLA after growth to saturation in liquid SD-TL. Tenfold serial dilutions of yeast cells harbouring the indicated constructs were spotted on synthetic dextrose medium selective for Y2H plasmids (TL) or on media selective for Y2H plasmids and a physical interaction between encoded proteins (TLH) or (TLA). Before spotting, cells were rinsed twice in sterile water to avoid carry over of nutrients from SD-TL medium. Mutant plasmids were recovered with a modified Qiagen miniprep protocol with glass beads and then shuffled in chemocompetent bacteria. A single bacterial transformant was then picked and grown to saturation in LB medium containing the appropriate selection (kanamycin for pGBKT7 and ampicillin for pGADT7). Plasmid DNA was subsequently isolated and sequence-verified. Expression of mutant Y2H pGBKT7 fusions and pGADT7 fusions was determined by western immunoblotting of yeast extracts with anti-Myc and anti-HA antibodies, respectively.
The identification of MEK1 rescue variants that interact with KSR1 W831R was also performed using the error-prone PCR mutagenesis approach coupled to the Y2H screening assay with the exception that the pGAD-KSR1
W831R was used as the bait and the rescue mutants were selected for autotrophy on either of -TLH or -TLA medium. This approach repeatedly identified two independent point mutations (M219V and N221Y) situated between the RAF phospho-acceptor sites (S218 and S222) in the activation segment (Extended Data Fig. 5a , b) that enabled binding to KSR1 W831R (Fig. 2b) . A saturation mutagenesis Y2H screen targeting residues 219-221 was then conducted to find tighter binders. Saturation mutagenesis of the human MEK1 activation segment was performed with a degenerated oligonucleotide with NNK-NNK-NNK sequence (N and K stand, respectively, for any base and for G/C) replacing the coding sequence of residues 219-221. This design allowed spanning of all amino-acid possibilities, while excluding two stop codons. It also diminished by eightfold the number of sequence combinations, preventing screen wobble base mutants different in base content but identical in amino-acid sequence. The degenerated sequence was incorporated by a two-step PCR to create a product corresponding to MEK1 cDNA flanked with pGBK homology arms. This library was screened against the pGAD-KSR1 W831R bait for rescue mutants. Protein expression and purification. WT and mutants of the BRS domain of human BRAF (residues 36-114) were expressed as TEV protease-cleavable GST fusions using a modified pGEX-2T vector. WT and mutants of the CC-SAM domain of human KSR1 (residues 32-178, denoted hCC-SAM) or mouse KSR1 (residues 25-170, denoted mCC-SAM) were expressed as TEV protease-cleavable 6× His tag fusions using a pPROEX vector. The human BRS domain/human CC-SAM domain chimaeras (KSR1 27-172 -BRAF ) connected by a (GS) 4 , (GS) 3 , or (GS) 2 linker were expressed as TEV-cleavable 6× His tag fusions using a pPROEX vector. The chimaeras allowed us to surmount the recurrent problem of crystallizing the isolated individual domains when using non-fused proteins in co-crystallization experiments. WT and mutant forms of the kinase domain of human MEK1 (residues 61-393, denoted MEK1-KD) were expressed as noncleavable C-terminal 6× His tag fusions using a pET28a vector. Expression constructs were transformed into BL21-CodonPlus DE3-RIL bacteria (Agilent Technologies) for protein production. Bacterial expression was induced overnight at 18 °C with 1 mM IPTG and was performed in LB or TB or M9 minimal media supplemented with [ 15 N]NH 4 Cl (Cambridge Isotopes) or M9 minimal media supplemented with l-selenomethionine for biochemical experimentation, NMR spectroscopy, or crystallography purposes, respectively.
BRS bacterial pellets were resuspended in 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM PMSF, 5 mM 2-mercaptoethanol and lysed by homogenization. Lysates were clarified by centrifugation at 4 °C for 40 min at 18,000g. Proteins were bound to glutathione affinity resin (GE Healthcare), eluted by cleavage of the GST tag with TEV, concentrated, and then buffer exchanged by size-exclusion chromatography (SEC) using a Superdex75 24 ml column (GE Healthcare) equilibrated in running buffer for NMR experiment (20 mM phosphate buffer, 100 mM NaCl, 0.5 mM TCEP, pH 6.5) or running buffer for crystallography (20 mM HEPES pH 7.5, 50 mM NaCl, 1 mM TCEP).
hCC-SAM and mCC-SAM bacterial pellets were resuspended in 50 mM HEPES pH 7.5, 500 mM NaCl, 1 mM PMSF, 20 mM imidazole, 5 mM 2-mercaptoethanol and lysed by homogenization. Lysates were clarified by centrifugation at 4 °C for 40 min at 18,000g. Proteins were purified by a two-step chromatography procedure using nickel-affinity chromatography (GE Healthcare) in 50 mM HEPES pH 7.5, 500 mM NaCl, 5 mM 2-mercaptoethanol (with an elution gradient up to 500 mM imidazole), followed by TEV protease treatment and then SEC on a Superdex75 24 ml column (GE Healthcare) equilibrated with 20 mM phosphate buffer, 100 mM NaCl, 0.5 mM TCEP, pH 6.5 running buffer.
Bacterial pellets of BRS:CC-SAM domain chimaeric constructs were resuspended in 50 mM HEPES pH 7.5, 500 mM NaCl, 1 mM PMSF, 1 mM TCEP, 5% glycerol and lysed by homogenization. Lysates were clarified by centrifugation at 4 °C for 40 min at 18,000g. Proteins were purified by the two-step procedure described for BRS GST fusion proteins with a final SEC buffer consisting of 20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP.
hMEK1 WT and F311S bacterial pellets were resuspended in 100 mM HEPES pH 7, 250 mM NaCl, 1 mM PMSF, 2.5% glycerol, 1 mM TCEP and lysed by homogenization. The lysate was clarified by centrifugation at 4 °C for 40 min at 18,000g. Proteins were purified by a two-step chromatography procedure using nickel-affinity chromatography (GE Healthcare). Proteins were eluted from the nickel-affinity column with lysis buffer supplemented with 500 mM imidazole, followed by SEC on a Superdex75 24 ml column (GE Healthcare) equilibrated with 20 mM HEPES pH 7.5, 250 mM NaCl, 1 mM TCEP running buffer.
Following SEC, all protein fractions corresponding to greater than 95% purity were pooled, concentrated, and flash frozen in liquid nitrogen. Protein concentration was determined by ultraviolet-visible absorption spectroscopy at 280 nm wavelength using a NanoDrop spectrophotometer (Thermo-Fisher Scientific) and theoretical extinction coefficients. ) with 1 μl of mother liquor of 0.1 M Bis-Tris pH 6.5, 2.0 M ammonium sulfate. X-ray diffraction was measured on a flash-frozen crystal cryo-protected in mother liquor containing 20% glycerol at 100 K on station 24-ID-C, NE CAT beamline at the Advanced Photon Source using 1.5418 Å X-ray wavelength. Data reduction was performed using HKL2000 (HKL Research). The BRS domain structure was solved using CCP4 (ref. 23 ) and ARCIMBOLDO Lite 24 .
Model building and refinement was performed using COOT 25 and PHENIX 26 , respectively (see Extended Data Fig. 9a for data collection and refinement statistics).
Unlabelled and l-selenomethionine-labelled CC-SAM:(GS) 4 :BRS fusion proteins were crystallized at 20 °C in sitting-drops by mixing 0.4 μl of protein (1 mM, 20 g l
) with 0.4 μl of mother liquor of 0.1 M Tris pH 7.5, 3.0 M sodium formate. X-ray diffraction was measured on a flash-frozen crystal cryo-protected in mother liquor containing 25% glycerol at 100 K on station 24-ID-C, NE CAT beamline at the Advanced Photon Source using 0.9791 Å X-ray wavelength. Data reduction was performed using the XDS package 27 . Phasing was performed by selenomethionine single-wavelength anomalous dispersion using HKL2MAP 28 and the SHELX pipeline 29 . The atomic model obtained by selenomethionine single-wavelength anomalous dispersion was then used as a search model for molecular replacement with a higher-resolution native data set using PHASER 30 . Phases were improved by density modification using ARP/wARP 31 .
Model building and refinement were performed using COOT 25 and PHENIX 26 , respectively. All models were validated using molprobity 32 . The data statistics and refinement details are reported in Extended Data Fig. 9a . Ramachandran statistics for all models were as follows. hBRS: 94.64% favoured, 5.36% allowed, 0% outliers; hCC-SAM-hBRS: 99.5% favoured, 0.5% allowed, 0% outliers. (GS) 2, (GS) 3 , and (GS) 4 fusions adopted the same oligomeric state in solution (Extended Data Fig. 9e) . NMR experiments. NMR experiments were performed at the University Health Network High Field NMR facility. NMR-HSQC spectra were recorded at 20 °C on an 800-MHz spectrometer or a 600-MHz Bruker AVANCE III spectrometer (supported by the Canada Foundation for Innovation). The 800-MHz and 600-MHz spectrometers were equipped with 5-mm TCI and 1.7-mm TCI CryoProbes, respectively. All NMR samples contained 200 μM or 100 μM of [ CC-SAM (using 800 MHz or 600 MHz, respectively) in 50 mM sodium phosphate pH 6.5, 100 mM NaCl, 0.5 mM TCEP, and 5% D 2 O. Data processing was conducted using NMRviewJ and NMRpipe 33 . NMR spectra were analysed using Analysis . Affinities were obtained by fitting CSPs of the HSQC titration spectra using Analysis 34, 35 . SEC followed by multi-angle light scattering analysis. CC-SAM:BRS chimaeric fusion and MEK1-KD WT and mutant proteins were analysed using a SEC followed by multi-angle light scattering (SEC-MALS) apparatus equipped with MiniDawn Treos and Optilab T-rEX detectors (Wyatt Technologies). CC-SAM:BRS chimaeric fusion samples were run at a concentration of 9 mg ml −1 in a buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP. MEK1-KD samples were run at a concentration of 4 mg ml −1 in a buffer containing 20 mM HEPES pH 7.5, 250 mM NaCl, 1 mM TCEP. Proteins were run on a WTC030S5 (Wyatt Technologies) column at a flow rate of 0.5 ml min −1
. Data were processed using Astra 6.0.3.16 software (Wyatt Technologies). Data analysis and structure rendering. BRET titration curves were analysed using Prism 5.04 (GraphPad Software) with one-site binding hyperbolic fitting of the data. BRET dose-response experiments with mCherry-MEK1 constructs were fitted using a log 10 (agonist) versus response function. Structure rendering was done using PyMol (Schrödinger) 36 and CHIMERA
37
. Coiled-coil predictions were done using the online COILS server. Sequence alignments were performed using the MUSCLE online server (http://www.drive5.com/muscle/). Alignments were edited using Jalview 38 or ALINE
Letter reSeArCH
Extended Data Figure 1 | MEK levels modulate the formation of BRAF F311S does not modulate dimerization of five biosensors comprising BRAF as the donor probe expressed with ARAF, BRAF, CRAF, KSR1, or KSR2 as acceptor probes. In c and g-l, BRET log 2 -transformed fold-changes were reported as a function of log 10 -transformed mCherry relative fluorescence units. Experiments were repeated at least three times. For gel source data, see Supplementary Fig. 1 .
Extended Data Figure 3 | Mutations in helix αG of MEK1 and KSR1  (F311S and W831R, respectively) Fisher Scientific) . d, e, WT KSR1 and the W831R mutant assemble to the same extent with the known interaction partners HSP90, CDC37, and 14-3-3, indicating that the protein fold of KSR1 is not overtly perturbed by the W831R mutation. Interaction partners were confirmed by mass spectrometry and by western immunoblotting. f, WT KSR1 and the W831R variant expressed in HEK293T cells show equal binding to the ATP analogue desthiobiotin-ATP as assessed using a Pierce Kinase Enrichment Kit (Thermo-Fisher Scientific). g, BRAF-KSR1-MEK1 complexes were purified to nearhomogeneity by immunoaffinity purification on anti-Flag-agarose resin after treatment of the transfected cells with GDC-0879 (10 μM). BRAF and KSR1 form near-stoichiometric complexes in the presence of MEK1 overexpression (compare lanes 3 and 4) . The KSR1 W831R mutant (lane 5) and the MEK1 F311S mutant (lane 7) but not the BRAF I666R mutant (lane 6) perturbed this near-stoichiometric interaction. Note that the BRAF-KSR1-MEK1 complex also associates at near-stoichiometric levels with endogenous 14-3-3 isoforms. In addition, in the absence of MEK1 overexpression, appreciable but sub-stoichiometric levels of endogenous MEK are detected by immunoblotting. Protein identity was determined by mass spectrometry. Asterisks indicate the position of non-specific proteins associating with the anti-Flag-agarose resin. h, The basal association of BRAF-KSR1 dimers (top panel, first lane) depends on endogenous MEK. Reducing MEK1 and MEK2 levels by short hairpin RNA (shRNA) interference (combination of shMEK1 and shMEK2) decreases the amount of Pyo-KSR1 co-purifying with Flag-BRAF. NT, non-target control shRNA. Experiments were repeated at least three times. For gel source data, see Supplementary Fig. 1 .
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Excel, GraphPad Prism 5.04 (curve fitting), Gen5 (data analysis), Jalview (sequence alignment and edition), ALINE (sequence alignment), MUSCLE (sequence alignment), COILS (coiled-coil prediction), PyMol 1.7.4.3 (structure rendering), CHIMERA (structure rendering), Astra 6.0.3.16 (SEC-MALS analysis), CCP4 (X-ray structure solution), ARCIMBOLDO Lite (X-ray structure solution). COOT (X-ray structure model building), PHENIX (X-ray structure model refinement), XDS (X-ray diffraction data processing), Molprobity (X-ray model validation), HKL2MAP (X-ray data phasing), SHELX (macromolecular phasing by SAD), PHASER (molecular replacement), ARP/wARP (electron density modification), MRviewJ (NMR data processing), NMRpipe (NMR data processing), Analysis (NMR HSQC analysis)
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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Policy information about availability of materials 8. Materials availability Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There are no restriction on materials availability.
